

# Alaska Medicaid Pharmacy and Therapeutics Committee

Meeting date February 18, 2005

Frontier Building, 3601 C Street; Room 880/890

## Agenda

Call in: 1-800-315-6338. Use access code 735#.

**Final**

**\*Drug classes to be discussed as time allows.**

**Call to order - Chair**

Richard Brodsky, MD

8:00 a.m.

**Roll call**

Richard Brodsky, MD

8:00 – 8:05

**Public Comment – Local Public / Local Physicians -**

(See guidelines on page 2)

**Public Comment - (See guidelines on page 2)**

Re-review Thiazolidinediones

Annette Paul, PharmD/FHSC

Time as needed

- Time for discussion & vote
- Vote on motions

**Public Comment - (See guidelines on page 2)**

Re-review Alpha-Glucosidase Inhibitors

Terry Babb, Pharm D / FHSC

Time as needed

- Time for discussion & vote
- Vote on motions

**Public Comment - (See guidelines on page 2)**

Re-review Biguanides

Terry Babb, Pharm D / FHSC

Time as needed

- Time for discussion & vote
- Vote on motions

**Public Comment - (See guidelines on page 2)**

Re-review Biguanides / Combination Agents

Terry Babb, Pharm D / FHSC

Time as needed

- Time for discussion & vote
- Vote on motions

**Public Comment - (See guidelines on page 2)**

Re-review Insulins

Terry Babb, Pharm D / FHSC

Time as needed

- Time for discussion & vote
- Vote on motions

**BREAK**

Approx 10:30 a.m.

**Public Comment - (See guidelines on page 2)**

Re-review Meglitinides

Terry Babb, Pharm D / FHSC

Time as needed

- Time for discussion & vote
- Vote on motions

**Public Comment - (See guidelines on page 2)**

Re-review Sulfonylureas- Second Generation

Terry Babb, Pharm D / FHSC

Time as needed

- Time for discussion & vote
- Vote on motions

**Public Comment - (See guidelines on page 2)**

Re-review Histamine-2 Receptor Antagonists

Terry Babb, Pharm D / FHSC

Time as needed

- Time for discussion & vote
- Vote on motions

**Public Comment - (See guidelines on page 2)**

Re-review Bisphosphonates

Terry Babb, Pharm D / FHSC

Time as needed

- Time for discussion & vote
- Vote on motions

**Discuss Rosuvastatin Safety Information**

Terry Babb, Pharm D / FHSC

Time as needed

**Final Comments by Chair or other members**

5 minutes

**Closing**

**Noon or before**

**GUIDELINES FOR PROVIDING COMMENT to the ALASKA P&T COMMITTEE**  
**February 18, 2005**

1. All interested speakers will be required to provide the Committee with the name of their organization, the speaker's relationship to the organization and topic area.
2. The time on the agenda for each agenda item is limited. An individual's comments to the committee are limited to a maximum of five (5) minutes in total.
3. Only one speaker "slot" will be available per meeting representing a single manufacturer or interest group. Within the allowable five (5) minute time period, multiple speakers may share this "slot".
4. NO reference or information as to pricing is allowed in any comment(s). Such information will be considered reason for immediately ending the comment opportunity.
5. It is requested that comment provided in relation to specific medications be directed toward how this product is clinically superior or the specific advantage(s) it offers, new evidence/research results or synergistic outcomes which have been demonstrated.
6. Written medical information is not accepted at the P&T meeting. This is to be submitted First Health prior to the meeting.